Abstract
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Andrew P. Hederman, Hannah M. Brookes, Harini Natarajan, Leo Heyndrickx, Kevin K. Ariën, Joshua A. Weiner, Amihai Rottenstreich, Gila Zarbiv, Dana Wolf, Tessa Goetghebuer, Arnaud Marchant, Margaret E. Ackerman
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
COVID-19 Mortality Update - United States, 2022
10.15585/mmwr.mm7218a4 · 2023
Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality
10.1016/j.cell.2020.10.052 · 2020
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
10.1038/s41591-021-01540-1 · 2021
Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants
10.1126/science.abj4176 · 2021
The effect of spike mutations on SARS-CoV-2 neutralization
10.1016/j.celrep.2021.108890 · 2021
Plasma Neutralization of the SARS-CoV-2 Omicron Variant
10.1056/nejmc2119641 · 2022
Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses
10.1126/scitranslmed.abn7842 · 2022
Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines
10.1038/s41467-022-31929-6 · 2022
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
10.1038/s41586-021-03398-2 · 2021
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
10.1038/s41586-021-03324-6 · 2021
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera
10.1016/j.cell.2021.02.037 · 2021
Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons
10.1056/nejmoa2104983 · 2021
Receipt of mRNA Covid-19 Vaccines and Risk of Spontaneous Abortion
10.1056/nejmc2113891 · 2021
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
10.1056/nejmoa2035389 · 2021
An mRNA Vaccine against SARS-CoV-2 - Preliminary Report
10.1056/nejmoa2022483 · 2020
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
10.1056/nejmoa2034577 · 2020
Association of Gestational Age at Coronavirus Disease 2019 (COVID-19) Vaccination, History of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, and a Vaccine Booster Dose With Maternal and Umbilical Cord Antibody Levels at Delivery
10.1097/aog.0000000000004693 · 2022
Safety and Effectiveness of Maternal COVID-19 Vaccines Among Pregnant People and Infants
10.1016/j.ogc.2023.02.003 · 2023
Systematic review and meta-analysis of the effectiveness and perinatal outcomes of COVID-19 vaccination in pregnancy
10.1038/s41467-022-30052-w · 2022
Estimation of COVID-19 mRNA Vaccine Effectiveness Against Medically Attended COVID-19 in Pregnancy During Periods of Delta and Omicron Variant Predominance in the United States
10.1001/jamanetworkopen.2022.33273 · 2022
The impact of maternal SARS-CoV-2 infection and COVID-19 vaccination on maternal-fetal outcomes
10.1016/j.reprotox.2022.10.003 · 2022
Maternal Vaccination and Risk of Hospitalization for Covid-19 among Infants
10.1056/nejmoa2204399 · 2022
Maternal vaccination: a review of current evidence and recommendations
10.1016/j.ajog.2021.10.041 · 2022
IgG placental transfer in healthy and pathological pregnancies
10.1155/2012/985646 · 2012
The Impact of IgG transplacental transfer on early life immunity
10.4049/immunohorizons.1700057 · 2018
Postacute Sequelae of SARS-CoV-2 in Children
2024
Multisystem Inflammatory Syndrome in U.S. Children and Adolescents
10.1056/nejmoa2021680 · 2020
SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland
10.1038/s41591-021-01666-2 · 2022
Pregnancy outcomes after SARS-CoV-2 infection in periods dominated by delta and omicron variants in Scotland: a population-based cohort study
10.1016/s2213-2600(22)00360-5 · 2022
Effects of COVID-19 vaccination during pregnancy on SARS-CoV-2 infection and maternal and neonatal outcomes: A systematic review and meta-analysis
10.1002/rmv.2434 · 2023
FcRn, but not FcγRs, drives maternal-fetal transplacental transport of human IgG antibodies
10.1073/pnas.2004325117 · 2020
Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies
10.1073/pnas.0606304103 · 2006
The MHC class I-related receptor, FcRn, plays an essential role in the maternofetal transfer of gamma-globulin in humans
10.1093/intimm/13.8.993 · 2001
FcRn: the MHC class I-related receptor that is more than an IgG transporter
10.1016/s0167-5699(97)01172-9 · 1997
Crystal structure of the complex of rat neonatal Fc receptor with Fc
10.1038/372379a0 · 1994
Dynamic changes of acquired maternal SARS-CoV-2 IgG in infants
10.1038/s41598-021-87535-x · 2021
Maternal Antibody Response, Neutralizing Potency, and Placental Antibody Transfer After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
10.1097/aog.0000000000004440 · 2021
Compromised SARS-CoV-2-specific placental antibody transfer
10.1016/j.cell.2020.12.027 · 2021
Assessment of Maternal and Neonatal Cord Blood SARS-CoV-2 Antibodies and Placental Transfer Ratios
10.1001/jamapediatrics.2021.0038 · 2021
Maternal and Neonatal SARS-CoV-2 Immunoglobulin G Antibody Levels at Delivery After Receipt of the BNT162b2 Messenger RNA COVID-19 Vaccine During the Second Trimester of Pregnancy
10.1001/jamapediatrics.2021.5683 · 2022
Decoding human-macaque interspecies differences in Fc-effector functions: The structural basis for CD16-dependent effector function in Rhesus macaques
10.3389/fimmu.2022.960411 · doi-reference
A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation
10.1016/j.jim.2019.07.002 · doi-reference
Distinct Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals
10.3389/fimmu.2020.618685 · doi-reference
A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples
10.1016/j.jim.2010.12.016 · doi-reference
Three doses of BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant
10.1038/s41541-022-00459-z · doi-reference
Optimization and qualification of an Fc Array assay for assessments of antibodies against HIV-1/SIV
10.1016/j.jim.2018.01.013 · doi-reference
Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles
10.1016/j.jim.2017.01.010 · doi-reference
Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1
10.1126/science.1187659 · doi-reference
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
10.1038/s41586-020-2349-y · doi-reference
High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples
10.1016/j.jim.2012.09.007 · doi-reference
Highly parallel characterization of IgG Fc binding interactions
10.4161/mabs.28808 · doi-reference
SARS-CoV-2 vaccination elicits broad and potent antibody effector functions to variants of concern in vulnerable populations
10.1038/s41467-023-40960-0 · doi-reference
Alternative pathway activation of the complement system in preterm infants with early onset infection
10.1203/00006450-199703000-00005 · doi-reference
Advantages and Limitations of the Neonatal Immune System
10.3389/fped.2020.00005 · doi-reference
Phagocytosis of neonatal pathogens by peripheral blood neutrophils and monocytes from newborn preterm and term infants
10.1038/pr.2013.145 · doi-reference
Off to a slow start: under-development of the complement system in term newborns is more substantial following premature birth
10.1016/j.imbio.2011.07.027 · doi-reference
Phagocytic ability of neutrophils and monocytes in neonates
10.1186/1471-2431-11-29 · doi-reference
Durability of Anti-Spike Antibodies in Infants After Maternal COVID-19 Vaccination or Natural Infection
10.1001/jama.2022.1206 · doi-reference
Effects of the timing of maternal SARS-CoV-2 infection and vaccination status on placental transfer of antibodies to neonates: A cross-sectional study
10.1016/j.ijid.2024.107098 · doi-reference
Timing of Maternal COVID-19 Vaccine and Antibody Concentrations in Infants Born Preterm
10.1001/jamanetworkopen.2023.52387 · doi-reference
Maternal-Fetal Outcomes and Antibody Transfer, Depending on the Trimester of SARS-CoV-2 Infection in Non-Vaccinated Women-A Danish Nationwide Prospective Cohort Study
10.3390/ijms26062533 · doi-reference
In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies
10.1016/j.cell.2021.06.021 · doi-reference
Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice against severe disease using Fc-mediated effector functions
10.1371/journal.ppat.1011569 · doi-reference
Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization
10.1172/jci141206 · doi-reference
A Covid-19 Milestone Attained - A Correlate of Protection for Vaccines
10.1056/nejmp2211314 · doi-reference
Correlates of Protection, Thresholds of Protection, and Immunobridging among Persons with SARS-CoV-2 Infection
10.3201/eid2902.221422 · doi-reference
Correlates of protection against SARS-CoV-2 infection and COVID-19 disease
10.1111/imr.13091 · doi-reference
Antigenic structure of the human coronavirus OC43 spike reveals exposed and occluded neutralizing epitopes
10.1038/s41467-022-30658-0 · doi-reference
Boosting of cross-reactive antibodies to endemic coronaviruses by SARS-CoV-2 infection but not vaccination with stabilized spike
10.7554/elife.75228 · doi-reference
Factors Affecting the FcRn-Mediated Transplacental Transfer of Antibodies and Implications for Vaccination in Pregnancy
10.3389/fimmu.2017.01294 · doi-reference
Placental transport of immunoglobulin G
10.1016/s0264-410x(03)00334-7 · doi-reference
Maternal-fetal transport of immunoglobulin G and its subclasses during the third trimester of human pregnancy
10.1111/j.1600-0897.1994.tb00873.x · doi-reference
Immunomodulation of Antibody Glycosylation through the Placental Transfer
10.3390/ijms242316772 · doi-reference
Selective transfer of maternal antibodies in preterm and fullterm children
10.1038/s41598-022-18973-4 · doi-reference
Reduced FcRn-mediated transcytosis of IgG2 due to a missing Glycine in its lower hinge
10.1038/s41598-019-40731-2 · doi-reference
Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases
10.1016/j.molimm.2015.03.255 · doi-reference
Update on Transplacental Transfer of IgG Subclasses: Impact of Maternal and Fetal Factors
10.3389/fimmu.2020.01920 · doi-reference
The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses
10.1038/s41577-022-00809-x · doi-reference
Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections
10.1016/j.celrep.2020.107725 · doi-reference
COVID-19 vaccine induced poor neutralization titers for SARS-CoV-2 omicron variants in maternal and cord blood
10.3389/fimmu.2023.1211558 · doi-reference